Author

Ken Imanak

Observed name: K. Imanak

OpenAlex ID: A5010567598

Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial

2023 · November McGarvey, Brian Ung, et al. · Advances in Therapy · 2

EE523 Incremental Annual State Level Cost Of Asthma And Future Projections In The United States

2025 · Ken Imanak, Tursynbek Nurmagambetov, et al. · Value in Health · 1

Healthcare Resource Utilization and Economic Burden of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel in Earlier-Line Settings in the KarMMa-3 Clinical Trial

2023 · Sikander Ailawadhi, November McGarvey, et al. · Blood

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 Study

2023 · Farrukh T. Awan, November McGarvey, et al. · Blood

CT-105 Post-Infusion Monitoring Costs and Health Care Resource Utilization (HCRU) by Site of Care (SOC) in Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 (TRANSCEND) Study

2023 · November McGarvey, Abraham Lee, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: CT-105 Post-Infusion Monitoring Costs and Health Care Resource Utilization (HCRU) by Site of Care (SOC) in Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 (TRANSCEND) Study

2023 · November McGarvey, Abraham Lee, et al. · Clinical Lymphoma Myeloma & Leukemia

EE162 Healthcare Resource Utilization and 2022 Cost Update of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel (IDE-CEL, BB2121) in KarMMa

2023 · N. McGarvey, K. Imanak, et al. · Value in Health

EPH70 Trends in Hospitalizations Related to Anxiety, Depression, and/or Substance Use Among Adult Inpatients from 2016-2020 in the United States

2023 · C. Lam, A. Lee, et al. · Value in Health

EPH236 Hospitalizations Related to Cytopenias Among the Multiple Myeloma Adult Inpatient Population in the United States

2023 · M. Gorbatov, A. Lee, et al. · Value in Health

Estimation of Long-Term Post-Infusion Costs of Care for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Following Administration of Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial

2022 · November McGarvey, Thomas Carattini, et al. · Blood

Works count: 10

Citation count: 3

H-index: 1

I10-index: